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east Ypt1p-interacting protein (Yip1p) belongs to a
conserved family of transmembrane proteins that interact with Rab GTPases. We encountered Yip1p as
a constituent of ER-derived transport vesicles, leading us
to hypothesize a direct role for this protein in transport
through the early secretory pathway. Using a cell-free assay
that recapitulates protein transport from the ER to the Golgi
complex, we find that affinity-purified antibodies directed
against the hydrophilic amino terminus of Yip1p potently
inhibit transport. Surprisingly, inhibition is specific to the
COPII-dependent budding stage. In support of this in vitro

observation, strains bearing the temperature-sensitive yip1-4
allele accumulate ER membranes at a nonpermissive
temperature, with no apparent accumulation of vesicle
intermediates. Genetic interaction analyses of the yip1-4
mutation corroborate a function in ER budding. Finally,
ordering experiments show that preincubation of ER
membranes with COPII proteins decreases sensitivity to
anti-Yip1p antibodies, indicating an early requirement for
Yip1p in vesicle formation. We propose that Yip1p has a
previously unappreciated role in COPII vesicle biogenesis.

Introduction
The eukaryotic secretory pathway responsively delivers proteins
and lipids to their correct destinations. Transport though
the secretory pathway is mediated by membrane vesicles
and/or tubules that form from a donor compartment and
fuse selectively with an acceptor. Specific cytosolic coat protein complexes and conserved membrane fusion factors such
as Rab GTPases and SNARE proteins are known to catalyze
many of these intracellular transport reactions (Mellman and
Warren, 2000). Although several of these transport components
are characterized, it is less clear how compartment-specific
factors interface with the conserved machinery and how
budding and fusion stages are coordinated.
Transport between the ER and Golgi complex in the early
secretory pathway also relies on GTPases and SNARE proteins.
More specifically, the Rab GTPase Ypt1p is required for
transport to the Golgi complex in yeast, and is localized primarily to Golgi membranes (Segev et al., 1988). To identify
other cellular factors that bind to Ypt1p, yeast two-hybrid
approaches uncovered a Ypt1p-interacting protein (Yip1p)
that is essential for transport through the early secretory
pathway (Yang et al., 1998). Yip1p is a 27-kD integral membrane protein predicted to span the membrane multiple
times. The amino-terminal hydrophilic domain of Yip1p
faces the cytosol and is sufficient for Ypt1p interaction.
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Yip1p also displays direct interactions with several other Rab
GTPases in yeast including Ypt31p and Sec4p. Yip1p binding
to Rabs depends on an intact carboxy-terminal CAAX motif
and prenylation of these GTPases (Yang et al., 1998; Calero
and Collins, 2002). The nucleotide status of the GTPase
seems less critical for these associations.
Yip1p not only associates with Rab GTPases, but forms a
heteromeric complex with a related integral membrane protein termed Yip1p-interacting factor (Yif1p). Yif1p shares a
common domain topology with Yip1p, binds to Rab GTPases
through a cytoplasmically exposed amino-terminal domain,
and is required for transport through the early secretory
pathway (Matern et al., 2000). Additional reports have
shown that yeast cells contain an extended family of Yip1p
related proteins that appear to form mixed heteromeric complexes with one another. This family displays some functional overlap and may act more broadly in intracellular
transport (Calero and Collins, 2002; Calero et al., 2002).
The subcellular distribution and molecular function of the
Yip family of proteins remains to be determined.
In this report, we investigate the role of Yip1p in protein
transport between the ER and Golgi complex. Using cellfree assays that recapitulate subreactions in this transport
process, we observed that antibody inhibition of Yip1p
activity and mutations within the amino-terminal cytosolic
domain of Yip1p inhibit COPII-dependent vesicle budding
Abbreviations used in this paper: Erv, ER vesicle; gp f, glycopro--factor;
Yif1p, Yip1p-interacting factor; Yip1p, Ypt1p-interacting protein.
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from the ER. Moreover, these Yip1p-specific inhibitors do not
directly interfere with the vesicle tethering or fusion stages of
ER-derived vesicles with Golgi membranes. Our in vivo analyses also support a role for Yip1p in budding from the ER.
These results are surprising in light of the fact that Ypt1p does
not appear to be required for COPII-dependent budding.

The Journal of Cell Biology

Results

Figure 1. Anti-Yip1p antibodies inhibit in vitro transport between
the ER and the Golgi complex at the budding stage. (A) Washed
wild-type (FY834) semi-intact cells containing [35S]gpf were
incubated with Recon proteins (COPII, Uso1p, and LMA1) and an
ATP regeneration system. After 75 min at 23C, the amount of
Golgi-modified [35S]gpf was measured to determine transport
efficiency. Where indicated, anti-Yip1p antibodies (40 g/ml),
preimmune IgGs (40 g/ml), or MBP-Yip1p (144 g/ml) were added
to reactions. (B) Semi-intact cells prepared as in A were incubated
with COPII or COPII plus Uso1p to measure budding and tethering
in the presence or absence of anti-Yip1p antibodies (20 g/ml).
After 30 min at 23C, freely diffusible vesicles containing [35S]gpf
were separated from semi-intact cell membranes by centrifugation
at 18,000 g and [35S]gpf quantified by Con A precipitation. (C) Vesicle

Anti-Yip1p antibodies inhibit transport to the Golgi
complex in vitro
Genetic and biochemical experiments have indicated a requirement for Yip1p in transport between the ER and the
Golgi complex. Conditionally lethal yip1 mutants display
defects in protein secretion, and morphological analyses
demonstrated that cells depleted of Yip1p accumulate membranes of the ER (Yang et al., 1998). Biochemical experiments have shown that Yip1p can physically associate with
Ypt1p (Yang et al., 1998), a small GTPase required for ER/
Golgi transport (Segev et al., 1988). Given these findings,
we sought to define the function of Yip1p more specifically
using a reconstituted cell-free assay that measures protein
transport to the Golgi complex. For this assay, washed
semi-intact cell membranes containing [35S]glycopro--factor (gpf) in the ER are incubated with purified factors
(COPII, Uso1p, and LMA1) to drive transport of [35S]gpf
to the Golgi complex (Barlowe, 1997). Upon delivery to the
Golgi complex, gpf receives outer-chain 1,6-mannose residues that can be immunoprecipitated with 1,6-mannose–
specific serum to quantify [35S]gpf transport (Baker et al.,
1988). To investigate Yip1p function in this assay, we first
prepared affinity-purified antibodies against the hydrophilic
amino terminus of Yip1p (aa residues 1–99). These antiYip1p antibodies were then added to cell-free transport assays in an attempt to neutralize Yip1p function. As seen in
Fig. 1 A, reconstituted transport was sensitive to anti-Yip1p
antibodies, whereas preimmune IgGs at comparable concentrations did not inhibit transport. The inhibition of antiYip1p antibodies was alleviated if purified MBP-Yip1p was
included in the reaction. This observation indicates MBPYip1p can compete with endogenous Yip1p for antibody
binding, and demonstrates that the antibodies act in a specific manner.
Subreactions in cell-free transport can be monitored by
following the sedimentation properties of membranes containing [35S]gpf (Barlowe, 1997). Incubation of washed
semi-intact cell membranes with purified COPII proteins
catalyzes the formation of diffusible vesicles that can be separated from larger membranes by centrifugation. When purified Uso1p is included in this reaction, a significant fraction
of the diffusible vesicles pellet with heavier membranes, providing a measurement of vesicle tethering. We found that
the inhibitory anti-Yip1p antibodies did not affect vesicle

budding as in B with increasing amounts of anti-Yip1p antibodies
(20–80 g/ml). No addition (NA) shows level of budding minus
COPII. (D) Vesicle budding as in B, except cytosol was used to drive
reactions. Where indicated, anti-Yip1p antibodies (40 g/ml) and
MBP-Yip1p (144 g/ml) were added.
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tethering to the Golgi complex, but instead inhibited the
budding of COPII vesicles (Fig. 1 B). Titrating the inhibitory effect of anti-Yip1p antibodies on budding showed that
increasing amounts of antibodies inhibited COPII-dependent vesicle budding in a dose-dependent manner (Fig. 1
C). We also examined the influence of anti-Yip1p antibodies
on vesicle budding when reactions were supplied with a
crude cytosolic fraction. As shown in Fig. 1 D, budding remained sensitive to the anti-Yip1p antibodies under this
condition. This observation indicates that other factors
present in a cytosolic extract cannot circumvent the inhibitory effect of the anti-Yip1p antibodies on vesicle budding.
The inhibition of budding by anti-Yip1p antibodies was
surprising, as there is no apparent requirement for Ypt1p in
the COPII-dependent vesicle-budding assay (Cao et al.,
1998). Therefore, we considered the possibility that these
anti-Yip1p antibodies interfered with budding in a nonspecific manner, perhaps by coating ER membranes and
preventing COPII association. Alternatively, the antibodies
could cross-link vesicles to ER membranes or to one another,
producing an aggregate that would pellet under the conditions of our budding assay. These effects would then mask
any later stage requirements for Yip1p in vesicle tethering or
fusion. To address these possibilities, we performed an additional series of experiments. First, it should be noted that
antibodies against other abundant vesicle proteins such as
Sec22p, Sed5p, and Erv29p do not block budding nonspecifically (Cao et al., 1998; Belden and Barlowe, 2001b; Liu and
Barlowe, 2002). Second, we prepared Fab fragments from
the affinity-purified anti-Yip1p antibodies and observed specific inhibition of the vesicle-budding stage of cell-free transport (unpublished data). Finally, we generated COPII vesicles containing [35S]gpf for use in second-stage transport
reactions to determine if anti-Yip1p antibodies influenced
any of the post-budding assays. As seen in Fig. 2 A, addition
of Uso1p to reactions containing isolated vesicles and wildtype acceptor membranes produced an 3.7-fold reduction
in diffusible vesicles, indicating efficient tethering of vesicles
to Golgi membranes (Fig. 2 A, compare column 1 with column 2). Vesicle tethering was unaffected by the addition of
anti-Yip1p antibodies in amounts that effectively block vesicle budding. In columns 4 and 5 of Fig. 2 A, vesicles and acceptor membranes or vesicles alone were combined with
anti-Yip1p antibodies in the absence of Uso1p. No reduction
in diffusible vesicles was observed for either condition, indicating that an antibody cross-linking event was not responsible for the observed decrease in vesicle budding.
We also examined the ability of the anti-Yip1p antibodies
to inhibit vesicle fusion in a two-stage reaction. Vesicles containing [35S]gpf were added to wild-type acceptor membranes with Uso1p and the fusion factor LMA1, in the presence or absence anti-Yip1p antibodies. As shown in Fig. 2 B,
the addition of Uso1p and LMA1 to the reaction stimulated
fusion 3.8-fold (Fig. 2 B, compare column 1 with column
2). The addition of anti-Yip1p antibodies to this reaction
did not inhibit fusion (Fig. 2 B, column 3). In contrast, affinity-purified antibodies against the SNARE protein Sec22p
effectively block vesicle fusion under these conditions as previously reported (Liu and Barlowe, 2002). Together, the results in Fig. 1 and Fig. 2 indicate that Yip1p is required for

Figure 2. Anti-Yip1p antibodies do not inhibit vesicle tethering or
vesicle fusion in a two-stage reaction. (A) COPII vesicles containing
[35S]gpf were synthesized from wild-type (FY834) membranes and
mixed with wild-type semi-intact cell acceptor membranes. Reactions
were incubated with Uso1p in the presence or absence of anti-Yip1p
antibodies (120 g/ml) where indicated. Freely diffusible vesicles
containing [35S]gpf were quantified by Con A precipitation. (B) COPII
vesicles prepared as in A were mixed with wild-type semi-intact cell
acceptor membranes. Reactions contained Uso1p and LMA1 in the
presence or absence of anti-Yip1p antibodies (120 g/ml) or antiSec22p antibodies (60 g/ml) where indicated. After 75 min at
23C, the amount of Golgi-modified [35S]gpf was measured to
determine fusion efficiency.

in vitro transport of [35S]gpf to the Golgi complex. These
data show that the anti-Yip1p antibodies potently and specifically inhibit the budding of COPII vesicles, suggesting a
role for Yip1p in vesicle biogenesis.
Anti-Yip1p antibodies block the COPII-dependent
budding of vesicle proteins
Next, we examined whether the inhibition of vesicle budding by the anti-Yip1p antibodies was restricted to [35S]gpf
monitored in the budding assay, or reflected a more complete block of vesicle biogenesis from ER membranes. Previous reports have shown that ER/Golgi SNARE proteins are
efficiently packaged into COPII vesicles (Barlowe et al.,
1994; Rexach et al., 1994). In addition, a group of conserved transmembrane proteins, termed ER vesicle (Erv)
proteins, are efficiently incorporated into COPII vesicles
(Rexach et al., 1994; Otte et al., 2001). We investigated
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whether anti-Yip1p antibodies affected the incorporation of
these proteins into COPII vesicles. Washed semi-intact cells
were incubated with COPII proteins and an energy regeneration system in the presence or absence of anti-Yip1p antibodies. The vesicles synthesized in each condition were then
isolated and analyzed by immunoblotting. As seen in Fig. 3,
COPII proteins catalyzed the efficient and specific incorporation of certain proteins into vesicles. The SNARE protein
Sec22p, as well as Erv25p, Erv41p, Yif1p, and Yip1p, were
efficiently packaged under these conditions (Fig. 3, lane 2).
The ER resident proteins Sec12p and Sec61p were not efficiently packaged into COPII vesicles, demonstrating selective
sorting in this budding assay. The presence of anti-Yip1p
antibodies in the reaction effectively inhibited budding of
all vesicle proteins examined, whereas preimmune IgGs at a
comparable concentration had no effect (Fig. 3, lane 3 and
lane 4). These results demonstrate the inhibition of vesicle
budding by the anti-Yip1p antibodies occurs in a general
manner, and is not restricted to [35S]gpf.
Figure 3. Anti-Yip1p antibodies block COPII-dependent budding
of vesicle proteins. COPII-budding reactions were performed from
wild-type semi-intact cells (FY834) in the presence or absence of
anti-Yip1p antibodies (40 g/ml) or preimmune IgGs (40 g/ml) as
indicated. One tenth of a total reaction (T), or budding reactions
without COPII proteins (lane 1), with COPII proteins (lane 2), with
COPII plus anti-Yip1p antibodies (lane 3), and with COPII plus preimmune antibodies (lane 4) were separated on a 12.5% polyacrylamide
gel. ER resident proteins (Sec61p and Sec12p) and vesicle proteins
(Sec22p, Erv25p, Erv41p, Yif1p, and Yip1p) were detected using
immunoblot. Asterisks indicate antibody heavy chain cross-reactivity
with secondary antibodies.

Figure 4. Themosensitive yip1-4 mutants display
morphological phenotypes characteristic of an
early block in the secretory pathway. Wild-type
and mutant cells were shifted to 37C for 40 min
and then fixed and prepared for EM as described
under the Materials and methods section. Representative thin sections are shown for each condition.
The white arrows in the sec18-1 panel point to
transport vesicles that have accumulated in this
strain. Note that the accumulation of vesicles was
absent in the yip1-4 and yip1-4 sec18-1 strains.
Bars, 1 m.

Mutant yip1-4 strains accumulate ER membranes
in vivo
We sought additional approaches to study the role of Yip1p
in transport between the ER and Golgi complex. The thermosensitive yip1-4 allele, which contains a single point mutation (E70K) in the cytoplasmic domain of Yip1p, blocks
secretion and growth when shifted to a restrictive temperature (Calero et al., 2003). To characterize the morphology of
transport intermediates that may accumulate in yip1-4
strains, thin-section EM was used under conditions that
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highlight membrane and vesicle structures (Kaiser and
Schekman, 1990). Upon shift to 37C for 40 min, yip1-4
strains show a massive proliferation of ER membranes (Fig.
4), which is commonly observed in the secretory mutants
that block vesicle production from the ER (Novick et al.,
1980). This type of ER accumulation was also reminiscent
of the karmellae-like ER exaggerations formed by overexpression of HMG1 in that the accumulating ER membrane
frequently formed multi-layered aggregates that were asymmetrically localized in the cell (Wright et al., 1988). However, unlike the HMG1 overexpression strains, the ER in
yip1-4 strains did not accumulate around the nucleus in an
ordered array, but appeared to extend into the cytoplasm,
sometimes lacking any obvious nuclear association, and was
often positioned underneath the plasma membrane. A very
similar terminal phenotype has been reported under conditions of Yip1p depletion after placing YIP1 expression under
GAL10 control (Yang et al., 1998).
Small 50–60-nm vesicles did not accumulate in the yip1-4
strain, but were clearly observed in a sec18 mutant (Fig. 4).
The sec18-1 mutation produces a strong vesicle accumulation phenotype because the corresponding Sec18p protein is
required for vesicle fusion (Wilson et al., 1989; Kaiser and
Schekman, 1990). When the yip1-4 and sec18-1 alleles were
combined in a single strain, we observed an ER accumulation phenotype without an accumulation of transport vesicles. This epistatic relationship between yip1-4 and sec18-1
indicates yip1-4 inhibits vesicle formation from the ER, and
therefore prevents the accumulation of vesicles that are characteristic of fusion mutants. A similar reversal of the sec18-1
vesicle accumulation phenotype has been reported when sec
mutants that specifically block COPII budding were combined with sec18-1 (Kaiser and Schekman, 1990). Thus, our
morphological experiments place YIP1 function in the vesicle-budding stage of transport between the ER and Golgi
compartments and before the action of Sec18p.
We also examined the distribution of an ER-localized protein in yip1-4 cells by fluorescence microscopy of GFPKDEL. When yip1-4 mutants were shifted to a restrictive
temperature for 60 min, striking elaborations of the ER were
apparent (Fig. 5 A) while nuclear structures remained intact.
Very similar elaborations of the ER were observed when
GFP-KDEL was expressed in a sec12 strain under restrictive
conditions (unpublished data). These observations are in accord with the images obtained by EM showing accumulation of ER membranes in yip1-4 mutants.
Redistribution of Golgi-localized proteins
to the ER in yip1-4 strains
Proteins that localize to early Golgi compartments continually cycle through the ER at varying rates. If export from the
ER is blocked, cycling proteins accumulate in the ER
(Schroder et al., 1995; Ward et al., 2001). For example,
Emp47p and Sed5p display Golgi localization patterns in
wild-type cells; however, in a sec12 strain shifted to the restrictive temperature, these proteins redistribute to the ER
(Schroder et al., 1995; Wooding and Pelham, 1998). We
used this approach to determine the influence of the yip1-4
mutation on the localization of Golgi-localized proteins. If
YIP1 is required for budding from the ER, we hypothesized

Figure 5. Distribution of GFP-tagged proteins in wild-type and
yip1-4 strains. (A) Fluorescence images of GFP-KDEL showing the
outline of ER membranes in wild-type (RCY1768) and yip1-4
(RCY1764) strains after 60 min at 37C. Hoechst stain for DNA
indicates nuclei remain intact in yip1-4 cells after a 60-min shift to
the restrictive temperature. (B) GFP-tagged versions of Sed5p, Gos1p,
and Sft2p were expressed in the yip1-4 strain and monitored by
fluorescence microscopy at 25C or after shift to 37C for 30 min.
Note the partial localization to perinuclear structures for GFP-Sed5p
and GFP-Gos1p upon shift to the restrictive temperature. (C) GFPGos1p shifts to a perinuclear distribution when ER export is blocked
in a sec12-4 strain, whereas GFP-Sft2p remains in a punctate pattern
as in the yip1-4 strain.

that early Golgi proteins would become ER-localized in the
absence of YIP1 function.
In this set of experiments, GFP-tagged versions of Sed5p,
Gos1p, and Sft2p were expressed in the yip1-4 mutant and
monitored by fluorescence at permissive and restrictive temperatures (Fig. 5 B). GFP-Sed5p displayed a typical punctate pat-
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ture shift as expected for a protein that functions in later Golgi
compartments (Wooding and Pelham, 1998). A very similar effect on the distribution of GFP-Gos1p and GFP-Sft2p was observed in sec12 strains (Fig. 5 C). These results provide further
support for a Yip1p requirement in export from the ER.

The Journal of Cell Biology

Yip1p cycles between the ER and Golgi compartments
Although Yip1p was detected in ER-derived vesicles, previous reports indicated that the protein was largely Golgi localized (Yang et al., 1998). We generated a GFP-Yip1p fusion protein under its native promoter to monitor the
location of Yip1p in live cells. Strains expressing this GFPYip1p fusion as the sole source of Yip1p activity displayed
growth rates that were comparable to wild-type strains (Fig.
6 A). Fluorescence imaging of GFP-Yip1p cells at various
cell cycle stages (Fig. 6 B) revealed both a punctate pattern
typical of Golgi-localized proteins and ring-like perinuclear
structures indicative of ER localization. We also examined
the fate of GFP-Yip1p in a sec12 mutant shifted to 37C
(Fig. 6 C). If GFP-Yip1p traffics through the ER, we would
expect it to accumulate in the ER when exit from this compartment is blocked. Indeed, GFP-Yip1p redistributed to
ER structures under this condition. Finally, we compared
the distribution of endogenous Yip1p under wild-type conditions or under a sec12 block using subcellular fractionation
schemes. Larger ER membranes pellet at a lower g-force
(13,000 g) than Golgi membranes (100,000 g) when cell
lysates are prepared under specified conditions (Wooding
and Pelham, 1998). As seen in Fig. 6 D, Yip1p was found in
both ER and Golgi fractions in wild-type strains, but shifts
to the ER fraction under a sec12 block. Together with our
budding experiments showing Yip1p is efficiently packaged
into ER-derived vesicles, these results indicate Yip1p cycles
between the ER and Golgi compartments and is dynamically localized to the early secretory pathway.

Figure 6. Yip1p cycles between the ER and Golgi compartments.
(A) GFP fused to the amino terminus of Yip1p (GFP-Yip1p) complements a yip1 strain. (B) Cells expressing GFP-Yip1p were analyzed
by fluorescence imaging. A punctate fluorescence pattern typical of
Golgi-localized proteins in addition to ring-like perinuclear structures
of the ER were observed. (C) GFP-Yip1p redistributes to perinuclear
structures when transport from the ER is blocked in a sec12 strain
shifted to 37C for 30 min (D) ER and Golgi membrane fractions
from WT and sec12-4. Cells were shifted to 37C for 45 min before
lysis and collection of membrane fractions. The contents of ER (P13)
and Golgi (P100) fractions were monitored by immunoblot. Sec61p
serves as an ER marker, whereas Och1p is a Golgi-localized protein.

tern at a permissive temperature, but upon temperature shift, a
distinct perinuclear localization emerged. Some GFP-Sed5p appeared to remain in spots and may represent Sed5p that functions in later Golgi compartments (Pelham, 2001). GFP-Gos1p
also redistributed to the ER when ER export was blocked, consistent with its proposed role in transport through early Golgi
compartments (McNew et al., 1998; Tsui et al., 2001). In contrast, GFP-Sft2p remained in a punctate pattern after tempera-

Mutant yip1-4 cells display a defect in COPII vesicle
budding in vitro
Our in vivo analyses of yip1-4 mutants indicated a block in
budding from the ER. Next, we examined the yip1-4 strain
in cell-free transport assays to further characterize transport
defects. As shown in Fig. 7 A, yip1-4 cells exhibited a significant defect in transport of [35S]gpf to the Golgi complex in
comparison to an isogenic wild-type strain at 23C. Specifically, the yip1-4 membranes displayed a 41% reduction in
[35S]gpf transport compared with wild-type. A similar result was obtained when these strains were compared at 29C,
thus, we could not replicate thermosensitivity of the yip1-4
allele in vitro (unpublished data). However, we examined the
ability of the yip1-4 strain to bud and tether COPII vesicles
to identify the stage at which transport was compromised
(Fig. 7 B). We observed that upon the addition of COPII
proteins, the wild-type membranes budded vesicles at an efficiency of 33%, whereas the yip1-4 membranes budded vesicles at an efficiency of only 9%. Importantly, translocation of [35S]gpf into the yip1-4 membranes was near the
wild-type level, indicating that the ER membranes were not
generally compromised. When the tethering factor Uso1p
was included in these reactions, we found that wild-type
membranes tethered 45% of the diffusible vesicles and
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when supplied with wild-type vesicles. Vesicles containing
[35S]gpf were generated from wild-type microsomes and purified on density gradients (Barlowe, 1997). The vesicles were
then added to wild-type or yip1-4 acceptor membranes in the
presence or absence of purified fusion factors. As shown in
Fig. 7 C, the combination of wild-type vesicles, wild-type acceptor membranes, and fusion factors produced a fusion efficiency of 15% (column 2). As shown in column 4, the
combination of wild-type vesicles, yip1-4 acceptor membranes, and fusion factors produced a comparable amount of
fusion (10%), indicating that the mutant cells retained
functional acceptor activity. These results suggest the Golgi
complex in the yip1-4 strain is functionally competent for
tethering and fusion in vitro. Based on these findings, we
conclude that the transport defect in the yip1-4 strain is most
specific to the budding stage, and that the membranes of the
early secretory pathway are not generally compromised.
The yip1-4 cells were also examined for their ability to
package proteins other than [35S]gpf into COPII vesicles.
COPII vesicles were generated from equivalent amounts of
wild-type or yip1-4 semi-intact cells and analyzed by immunoblot. As shown in Fig. 8, wild-type membranes efficiently
packaged Sec22p, Erv25p, Erv46p, Yif1p, and Yip1p into
vesicles in a COPII-dependent fashion. In contrast, yip1-4
membranes packaged these vesicle proteins at significantly
lower efficiencies upon reconstitution of COPII budding.
This result mirrors the decrease observed in packaging of
[35S]gpf, indicating an overall defect in COPII vesicle biogenesis. In summary, the in vitro budding defects caused by
the yip1-4 mutation are in accord with the phenotypes observed by microscopic inspection of the yip1-4 strain and
with our observation that anti-Yip1p antibodies block the
production of COPII vesicles in vitro.
Figure 7. yip1-4 membranes display a defect in COPII vesicle
budding in vitro. (A) Washed semi-intact cells containing [35S]gpf
were prepared from wild-type (RCY1768) and yip1-4 (RCY1764)
strains. Semi-intact cells were incubated with COPII proteins,
Uso1p, LMA1, and an ATP regeneration system. After 75 min at
23C, the amount of Golgi-modified [35S]gpf was measured to
determine transport efficiency. (B) Semi-intact cells from wild-type
and mutant strains were prepared as in A and incubated with COPII
or COPII plus Uso1p to measure vesicle budding and tethering.
(C) COPII vesicles containing [35S]gpf were synthesized from wildtype microsomes and purified on density gradients. Purified vesicles
were mixed with wild-type or yip1-4 semi-intact cell acceptor
membranes in second-stage assays in the presence or absence of
Uso1p and LMA1. After 75 min at 23C, the amount of Golgi-modified
[35S]gpf was measured to determine transport efficiency.

yip1-4 membranes tethered 47% of the diffusible vesicles.
These results indicate that the yip1-4 membranes can effectively tether COPII vesicles to the Golgi, but are defective in
their ability to bud COPII vesicles from ER membranes.
Given that the yip1-4 strain exhibited a budding defect
even at the permissive temperature of 23C, we were concerned that this defect could be an indirect consequence of
this point mutation on both ER and Golgi membranes. To
further monitor the integrity of Golgi membranes, we also
determined the acceptor activity of yip1-4 membranes

Genetic interaction analysis of yip1-4
The growth phenotype of strains that combine two distinct
mutations can indicate a functional connection between two

Figure 8. COPII-dependent budding of vesicle proteins is reduced
in the yip1-4 strain. COPII-budding reactions in wild-type (RCY1768)
or yip1-4 (RCY1764) semi-intact cells. One tenth of a total reaction
(T), budded vesicles isolated after incubation with COPII proteins
(), or a mock reaction without COPII proteins () were separated
on a 12.5% polyacrylamide gel. Sec61p (ER resident protein) and
Sec22p, Erv25p, Erv46p, Yif1p, and Yip1p (vesicle proteins) were
detected by immunoblot.
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Table I. Summary of genetic interactions

The Journal of Cell Biology

Allele

Figure 9. Genetic interaction analysis of yip1-4. Strains carrying
a thermosensitive mutation in genes involved in ER/Golgi transport
were combined with a yip1 allele together with a wild-type YIP1
on a URA3 plasmid. Strains also contained vector only, wild-type
YIP1 LEU2 vector, or a yip1-4 LEU vector. All transformants were
assessed by plasmid shuffling on 5-fluorouracil at 25C. Plates containing yip1-4 sec17ts double mutants are shown as an example
where no genetic interaction was observed. In contrast, yip1-4
sec12-4 double mutants are shown as an example of complete
lethality between two mutants. A summary of genetic interaction
results is shown in Table I.

genes. To test if the yip1-4 allele influences the growth properties of other ER/Golgi transport mutants, specific mutants
were combined with yip1-4. The double mutants were constructed in haploid strains in which viability was ensured by
expression of YIP1 from an extrachromosomal URA3-linked
plasmid. In these strains, loss of the YIP1-URA3 plasmid can be
scored by growth on media containing 5-fluorouracil (5-FOA)
and demonstrates viability of the double mutant. As examples
of this approach, no growth of the yip1-4 sec12-4 strain was
observed on 5-FOA plates, whereas viable yip1-4 sec17ts colonies were observed (Fig. 9). This result indicates that yip1-4
displays a synthetic lethal relationship with the budding mutant sec12-4. Several other trafficking mutants that act in specific stages of transport between the ER and Golgi complex
have been characterized. We constructed pair-wise combinations of these mutants with yip1-4 and tested for growth on
5-FOA media (Table I). Interestingly, we observed synthetic
lethal relationships between yip1-4 and mutants involved in
COPII budding from the ER, including sec12-4, sec13-1, and
sec23-1. The only other lethal combinations observed were
with the sec21-1 and uso1-1 mutations, which act in COPIand COPII-dependent transport pathways, respectively (Hosobuchi et al., 1992; Cao et al., 1998). A variety of other ER/
Golgi mutants did not display synthetic lethality when combined with yip1-4, indicating specificity in the interactions detected. These genetic tests provide further evidence for Yip1p
function in vesicle budding from the ER and are consistent
with our biochemical and morphological experiments.
Preincubation of membranes with COPII results in a
decrease in sensitivity to anti-Yip1p antibodies
Our experiments establish a role for Yip1p in vesicle budding from the ER. To further refine the stage at which
Yip1p functions during the process of COPII vesicle biogenesis, we attempted to order the temporal requirements for
the COPII proteins and Yip1p activity. Wild-type ER mem-

sec12-4
sec13-1
sec23-1
ypt1-3
sec16-2
ret1-1
sec20-1
sec21-1
sec17ts
sec18-1
sec22ts
bos1-1
sed5ts
bet3-1
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sec34-2
sec35-1
bet1-1

Viability at 25C in combination
with yip1-4
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branes containing [35S]gpf were preincubated with either
COPII or anti-Yip1p antibodies for 5 min at 15C. In a second incubation, factors were then added to each condition,
and the reaction proceeded for an additional 25 min before
vesicle budding was quantified. As shown in Fig. 10 A, preincubation of membranes with COPII proteins followed by
buffer produced a vesicle budding efficiency of 23%. Simultaneous addition of COPII proteins and anti-Yip1p antibodies reduced the budding efficiency to 5%. Similarly,
preincubation of membranes with anti-Yip1p antibodies for
5 min followed by the addition of COPII proteins inhibited
vesicle budding. Notably, preincubation of membranes with
COPII followed by the addition of anti-Yip1p antibodies
produced a budding efficiency of 22%, very similar to the
control COPII reaction. One explanation for this result may
be that a majority of vesicle budding occurred during the
5-min COPII preincubation. In this way, second-stage addition of the anti-Yip1p antibodies would have little or no effect. To address this issue, we measured COPII budding after a 5-min incubation at 15C and found that the level of
budding only reached 8% during the COPII preincubation stage (Fig. 10 A). It should also be noted that preincubation of membranes with COPII proteins on ice did not
produce resistance to anti-Yip1p antibodies. Therefore, we
conclude that membranes preincubated with COPII proteins at elevated temperatures become insensitive to antiYip1p antibodies. These observations suggest that Yip1p is
required early in the budding reaction.
Next, we investigated the possibility that an individual
COPII component was responsible for producing the decrease in sensitivity to anti-Yip1p antibodies during the preincubation step. Given the role of Sar1p in initiating coat assembly, we tested Sar1p as a candidate for this activity.
Wild-type ER membranes containing [35S]gpf were preincubated with Sar1p or anti-Yip1p antibodies for 5 min at
15C. In a second incubation, factors were added to each
condition, and then budding reactions continued for 25
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alone decreases sensitivity to anti-Yip1p antibodies; however, preincubation with all of the COPII components provides greater resistance.
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Figure 10. Preincubation of donor membranes with COPII
produces a decrease in sensitivity to anti-Yip1p antibodies.
(A) Washed semi-intact cells containing [35S]gpf were prepared
from a wild-type strain (FY834) and treated with either COPII or
anti-Yip1p antibodies (40 g/ml) for 5 min at 15C. Secondary
factors were then added as indicated, and the reactions proceeded
for an additional 25 min. Freely diffusible vesicles containing
[35S]gpf were then separated from semi-intact cell membranes by
centrifugation and quantified by Con A precipitation. (B) Semi-intact
cells prepared as in A were treated with Sar1p or anti-Yip1p antibodies alone (40 g/ml) for 5 min at 15C. Secondary factors were
then added and diffusible vesicles were quantified as in A.

min. As shown in Fig. 10 B, preincubation of membranes
with Sar1p alone followed by addition of buffer produced a
budding efficiency of 14%. Preincubation of membranes
with Sar1p followed by the secondary addition of Sec23/24p
and Sec13/31p stimulated budding to an efficiency of
28%. In contrast, preincubation of membranes with
Sar1p and anti-Yip1p antibodies followed by secondary addition of Sec23/24p and Sec13/31p produced a budding efficiency of 8%. Interestingly, preincubation of membranes
with Sar1p followed by addition of Sec23/24p, Sec13/31p,
and anti-Yip1p antibodies yielded a budding efficiency of
17%, which is intermediate when compared with the secondary addition of Sec23/24p and Sec13/31p alone. We
also measured the amount of budding during the 5-min
Sar1p preincubation stage and observed an 5% budding
efficiency. Therefore, the amount of vesicle budding that occurred during the Sar1p preincubation step cannot account
for the fraction of vesicle budding that becomes insensitive
to anti-Yip1p antibodies during the second stage. These results indicate that preincubation of membranes with Sar1p

The Yip1 family of proteins is widespread in nature and has
been implicated in Rab/Ypt function (Yang et al., 1998;
Matern et al., 2000; Calero and Collins, 2002; Calero et al.,
2002). Although these reports indicate that Yip1p and Yif1p
are essential for transport through the early secretory pathway, their mechanisms of action remain to be elucidated.
We had encountered the Yip1p and Yif1p proteins as constituents of ER-derived transport vesicles in experiments to
identify proteins involved in ER/Golgi transport (Otte et al.,
2001). Given that these proteins appear to cycle between the
ER and Golgi compartments as well as interact with Ypt1p,
we hypothesized that Yip1p would participate in a vesicle
tethering and/or membrane fusion stage. Surprisingly, our
experiments indicate that Yip1p function is required for
biogenesis of COPII-derived vesicles. Antibodies directed
against the amino-terminal cytosolic domain of Yip1p potently inhibited budding of COPII vesicles in assays that followed packaging of the soluble secretory cargo gpf and
other integral membrane vesicle proteins. Vesicle tethering
and fusion were not significantly affected by the presence of
anti-Yip1p antibodies.
Genetic analyses provided an independent line of evidence
for Yip1p function in vesicle budding. The thermosensitive
yip1-4 allele caused an accumulation of ER membranes with
no apparent accumulation of 50–60-nm transport vesicle intermediates. When the yip1-4 mutation was combined with
the vesicle accumulating sec18-1 mutation, the double mutant accumulated ER structures when shifted to restrictive
temperatures. This result demonstrates a requirement for
YIP1 in the production of vesicles that accumulate in sec18-1
cells. Furthermore, pair-wise combinations of yip1-4 with
other ER/Golgi transport mutants revealed specific interactions with genes (SEC12, SEC13, and SEC23) involved
in formation of COPII vesicles. Mutations that influence COPI vesicle biogenesis (SEC21) and Golgi tethering
(USO1) also displayed synthetic lethal relationships with
yip1-4, revealing potential roles for Yip1p in Golgi structure
or function. Finally, in vitro analysis of the yip1-4 allele revealed a significant defect in COPII-dependent vesicle budding, a result that is in good accord with the antibody inhibition analysis. Based on these observations, we propose that
Yip1p acts in vesicle biogenesis and may be required for the
assembly of coat structures, or possibly in the scission of
coated vesicles from the ER.
Our findings are unexpected, given that much of the current data regarding Yip1p suggest a role for this protein in
regulating aspects of Rab GTPase function. Indeed, Yip1p
was originally identified as a Ypt1p- and Ypt31p-binding
protein using yeast two-hybrid screens (Yang et al., 1998).
Subsequent reports identified Yif1p as a Yip1p-binding partner, and it has been proposed that a Golgi-localized Yif1p–
Yip1p complex acts to bind Ypt1p and Ypt31p to facilitate
vesicle docking and fusion (Matern et al., 2000). More recent data demonstrate the presence of an extended family of
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Yip1-related proteins that form mixed heteromeric complexes with one another (Calero et al., 2002). Yip1p and the
Yip1-related proteins interact with multiple Rabs and in a
manner that depends on carboxy-terminal prenylation of the
Rab protein. Based on these observations, the Yip1 family of
proteins has been proposed to act in the pathway by which
Rab proteins are recruited to membrane compartments
(Calero et al., 2002). Analyses on the mammalian homologue of yeast Yip1p have been undertaken as well. The
mammalian protein Yip1A shares 31% identity with yeast
Yip1p and functionally complements the loss of yeast YIP1
(Calero et al., 2003), indicating a functional conservation of
mechanism. Interestingly, Yip1A localizes to vesicular structures composing ER export sites, and interacts with the
Sec23/24 subunit of the mammalian COPII complex (Tang
et al., 2001). The authors of this report suggest that Yip1A is
involved in the regulation of ER/Golgi traffic at the level of
ER exit sites. This conclusion is consistent with our findings
that inhibitors of yeast Yip1p function block COPII-dependent budding from the ER and provides support for the hypothesis that Yip1p acts in COPII vesicle biogenesis.
If Yip1p functions in the process of vesicle budding, how
are Yip1p interactions with Rab GTPases integrated into this
model? Rab proteins have been traditionally thought to act
after vesicle formation to regulate the subsequent targeting
and fusion of vesicles to their acceptor membranes (Segev,
2001). However, recent evidence has also suggested a role for
Rab proteins in the process of vesicle formation. For example, experiments in mammalian cells indicate that Rab1 acts
during budding to program COPII vesicles for docking and
fusion competency. Here, Rab1 activity was proposed to recruit the vesicle tethering factor p115 into COPII vesicles
to promote targeting to the Golgi apparatus (Allan et al.,
2000). Other reports implicate Rab9 in coordinating cargo
selection with vesicle formation. Specifically, the authors of
this paper suggest that activated Rab9 binds directly to the
protein TIP47, which in turn facilitates the recruitment of
the mannose-6-phosphate receptor into a forming vesicle
(Carroll et al., 2001). Taking these observations into account
when considering Yip1p function, a model can be envisioned in which Yip1p acts to recruit Rabs/Ypts into forming
transport vesicles. In this way, vesicle biogenesis would be
coupled to the incorporation of cargos necessary for the
subsequent docking and fusion of the vesicle. If the ability
of Yip1p to recruit Rabs into forming vesicles is inhibited,
this might then cause overall vesicle formation to become
blocked as well. However, it should be noted that other vesicle proteins required for subsequent fusion, such as the
SNARE proteins Sec22p, Bos1p, Bet1p, rbet1, and membrin, can be efficiently depleted from forming COPII vesicles, yet vesicle formation is not compromised (Allan et al.,
2000; Liu and Barlowe, 2002; Miller et al., 2002).
Although some of the data support a role for Rab proteins
in vesicle formation, additional reports suggest that certain
Rabs are not required for budding, but are required for the
docking and fusion of transport vesicles. For example, sec4
and ypt1 thermosensitive mutant strains accumulate transport vesicles at nonpermissive temperatures (Novick et al.,
1980; Becker et al., 1991). These observations indicate that
Sec4p and Ypt1p are not required for the formation of vesi-

cles that accumulate, but instead act to fuse vesicles to the
correct target membrane. In vitro experiments also demonstrate that inhibition of Ypt1p activity does not block formation of COPII vesicles, but inhibits post-budding stages of
transport to the Golgi (Rexach and Schekman, 1991; Segev,
1991; Cao and Barlowe, 2000). Together, these results argue against a requirement for Ypt1p in COPII vesicle formation and suggest Yip1p does not rely on Ypt1p in this stage
of transport.
During the course of our investigation, a similar analysis
of Yip1p and Yif1p function in ER/Golgi transport was reported (Barrowman et al., 2003). This report showed that
antibodies directed against Yip1p or Yif1p blocked transport
to the Golgi complex, but only reduced budding efficiencies
by one half. Interestingly, the vesicles formed in the presence
of their inhibitory antibodies failed to fuse with Golgi membranes. In agreement with our findings, their anti-Yip1p antibodies did not inhibit vesicle tethering or fusion when
added after vesicle production. The authors concluded that
the Yip1p–Yif1p complex is required during vesicle formation to produce fusion competent vesicles (Barrowman et
al., 2003). Although we cannot easily explain the differential
effects of anti-Yip1p antibodies on the level of vesicle budding, both reports indicate a role for Yip1p function during
COPII vesicle biogenesis. Additional experiments will be
needed to clarify the role of Yip1p in post-budding transport
stages.
Barrowman and colleagues also reported that depletion of
cellular Yip1p did not affect membrane binding or localization of Ypt1p (Barrowman et al., 2003). Similarly, we have
observed that thermosensitive mutations in Yip1p and Yif1p
as well as antibodies directed against Yip1p did not inhibit
Ypt1p membrane association in vitro (unpublished data).
Although it is possible that other Yip family members may
drive membrane association of Ypt1p in the absence of
Yip1p and Yif1p, it may be useful to consider a model for
Yip1p function in budding that is independent of Ypt1p or
Rab protein activity. It is also possible that Yip1p serves as a
regulatory checkpoint in vesicle budding to ensure that ERderived vesicles can ultimately interact with Rab GTPases.
In such a model, the Rab protein, per se, may not be required for vesicle budding, but a Rab-binding activity would
be required.
The production of COPII-coated vesicles has been extensively studied in reconstituted budding reactions that use
purified COPII proteins and ER microsomes or defined
synthetic liposomes as the source of donor membrane
(Matsuoka et al., 1998). In contrast to microsomes, budding
from synthetic liposomes requires addition of nonhydrolyzable analogs of GTP to prolong the Sar1p-GTP state until
COPII coats assemble. In addition, synthetic liposomes with
an acidic phospholipid content that approximates the composition of ER membranes must be used in the minimal
budding reaction. Given these distinct requirements, Yip1p
could serve a role in stabilizing Sar1p-GTP during vesicle
formation from microsomal membranes, or it could influence local lipid concentrations at transitional ER sites. Further investigations are required to fully define the mechanism
of Yip1p in COPII-dependent budding from the ER. One
approach may be to accumulate arrested budding intermedi-
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ates in the presence of anti-Yip1p antibodies. Such intermediates could then be characterized biochemically and morphologically to provide further insights into Yip1p function.

fractionation experiments, ER (P13) and Golgi (P100) fractions were prepared as described previously (Belden and Barlowe, 2001a), except that
pellets were resuspended in 0.15 ml SDS-PAGE sample buffer.

In vitro vesicle budding, tethering, and transport assays

Materials and methods
Yeast strains and media
Yeast strains used in this report are listed in Table II. Unless noted otherwise, cultures were grown at 25C (for mutant strains) or 30C (for wildtype strains) in rich yeast extract, peptone, dextrose medium (1% Bactoyeast extract, 2% Bacto-peptone, and 2% dextrose). Standard yeast (Sherman,
1991) and cloning protocols (Ausubel et al., 1987) were used.
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Antibodies and immunoblotting

Antibodies against 1,6-mannose linkages (Cao et al., 1998), Sec12p,
Sec61p, Erv25p, Erv41p, Erv46p, Och1p (Otte et al., 2001), Yif1p (Matern
et al., 2000), and Sec22p (Liu and Barlowe, 2002) have been described
previously. pAbs were raised against a GST-Yip1p (amino-terminal 1–99
aa) fusion protein expressed from plasmid pGEX-2T-YIP1 in Escherichia
coli. The fusion protein was purified according to the manufacturer’s specifications (Amersham Biosciences) and was used to immunize rabbits by
standard procedures (Covance). Polyclonal anti-Yip1p antibodies were affinity purified on an Affi-Gel 15 column with maltose-binding protein–
Yip1p fusion (MBP-Yip1p) coupled as described by the manufacturer (BioRad Laboratories). MBP-Yip1p (amino-terminal 1–99 aa) was generated
using the expression vector pMAL-c2x (New England Biolabs, Inc.). The
fusion protein was purified according to the manufacturer’s specifications.
Affinity-purified anti-Yip1p Fab fragments and preimmune IgGs were prepared as described previously (Harlow and Lane, 1988). In membrane

Yeast semi-intact cells from wild-type and mutant strains were prepared as
described previously (Baker et al., 1988). Vesicle budding, tethering, and
fusion assays following [35S]gpf were published previously (Barlowe,
1997; Cao et al., 1998). For two-stage fusion assays with wild-type and
yip1-4 acceptor membranes, wild-type vesicles containing [35S]gpf were
first isolated from density gradients (Barlowe, 1997). Vesicles were then
added to acceptor membranes to measure fusion (Cao and Barlowe,
2000). Experiments to assay packaging of proteins into vesicles by Western
blot were performed as described previously (Liu and Barlowe, 2002) using semi-intact cell membranes. For ordering experiments, wild-type semiintact cells containing translocated [35S]gpf were first incubated with either COPII proteins or anti-Yip1p antibodies (40 g/ml) for 5 min at 15C.
Secondary factors were then added, and cells were incubated at 23C for
an additional 25 min. Reactions were then processed to measure the level
of freely diffusible vesicles (Cao et al., 1998). For in vitro assays, data
points are the average of duplicate determinations and the error bars represent the range.

Microscopy
For EM experiments, cells were grown overnight to a final cell density of
0.4–0.7 A600. After shift to the restrictive temperature, cells were washed
once with buffer (0.1 M Pipes, 0.1 M sorbitol, and 50 mM KPi, pH 7.3) and
then fixed with fixative (2% glutaraldehyde, 2% PFA, 0.1 M Pipes, pH 6.8,
0.1 M sorbitol, 1 mM MgCl2, 1 mM CaCl2, and 10 M CuCl2) for 1 h at RT
and then overnight at 4C. The cell walls were removed by treatment with

Table II. Yeast strains used in this paper
Strain
FY834
RCY927
RCY1610
RCY1612
RCY1633
RCY1634
RCY1764
RCY1768
RCY2057
RCY2141
RCY2143
RCY2146
RCY2153
RCY2226
RCY2232
RCY2234
RCY2237
RCY2239
RCY2258
RCY2259
RCY2303
RCY2318
RCY2321
RCY2325
RCY2326
RCY2384
RCY2386
RCY2389
RCY2474
RCY2390
RCY2400

Genotype

Source

MAT his3200 ura3-52 leu21 lys2202 trp163
MATa sec21-1 ura3-52 leu2-3,112
MAT YIP1KANR ura3-52 leu2-3,112 [URA3 CEN YIP1]
MATa YIP1KANR ura3-52 leu2-3,112 [URA3 CEN YIP1]
MATa YIP1KANR ura3-52 leu2-3,112 his200 [URA3 CEN YIP1 GDI1]
MAT YIP1KANR ura3-52 leu2-3,112 his200 [URA3 CEN YIP1 GDI1]
MATa ura3-52 leu2-3,112 YIP1KANR [pRS315 yip1-4]
MATa ura3-52 leu2-3,112 YIP1KANR [pRS315 YIP1]
MATa YIP1KANR ura3-52 leu2-3,112 his200 lys2-801 [URA3 CEN YIP1]
MAT sec12-4 YIP1KANR ura3-52 leu2-3,112 [URA3 CEN YIP1]
MAT sec18-1 YIP1KANR ura3-52 leu2-3,112 [URA3 CEN YIP1]
MAT sec21-1 YIP1KANR ura3-52 leu2-3,112 his200 [URA3 CEN YIP1 GDI1]
MATa sec13-1 YIP1KANR ura3-52 leu2-3,112 [URA3 CEN YIP1]
MATa sec17ts YIP1KANR ura3-52 leu2-3,112 lys2 [URA3 CEN YIP1 GDI1]
MATa sec22ts YIP1KANR ura3-52 leu2-3,112 [URA3 CEN YIP1 GDI1]
MATa sec16-2 YIP1KANR ura3-52 leu2-3,112 lys2-801 his [URA3 CEN YIP1 GDI1]
MATa sec23-1 YIP1KANR ura3-52 leu2-3,112 his [URA3 CEN YIP1 GDI1]
MAT ypt1-3 YIP1KANR ura3-52 leu2-3,112 his200 [URA3 CEN YIP1 GDI1]
MAT sec18-1 YIP1KANR ura3-52 leu2-3,112 [LEU2 CEN YIP1]
MAT sec18-1 YIP1KANR ura3-52 leu2-3,112 [LEU2 CEN yip1-4]
MAT sec20-1 YIP1KANR ura3-52 leu2-3,112 [URA3 CEN YIP1 GDI1]
MATa bos1-1 YIP1KANR ura3-52 leu2-3,112 his200 [URA3 CEN YIP1 GDI1]
MAT bet3-1 YIP1KANR ura3-52 leu2-3,112 his [URA3 CEN YIP1 GDI1]
MATa sec17ts YIP1KANR ura3-52 leu2-3,112 lys2 [LEU2 CEN YIP1]
MATa sec17ts YIP1KANR ura3-52 leu2-3,112 lys2 [LEU2 CEN yip1-4]
MAT sed5ts YIP1KANR ura3-52 leu2-3,112 his [URA3 CEN YIP1 GDI1]
MATa ret1-1 YIP1KANR ura3-52 leu2-3,112 trp1 [URA3 CEN YIP1 GDI1]
MATa uso1-1 YIP1KANR ura3 leu2 his200 lys2 [URA3 CEN YIP1 GDI1]
MAT bet1-1 YIP1KANR ura3 leu2 his200 [URA3 CEN YIP1 GDI1]
MAT sec35-1 YIP1KANR ura3 leu2 his200 lys2 [URA3 CEN YIP1 GDI1]
MATa sec34-2 YIP1KANR ura3 leu2 his200 lys2 [URA3 CEN YIP1 GDI1]

Winston et al. (1995)
This paper
This paper
This paper
This paper
This paper
Calero et al. (2003)
Calero et al. (2003)
This paper
This paper
This paper
This paper
This paper
This paper
This paper
This paper
This paper
This paper
This paper
This paper
This paper
This paper
This paper
This paper
This paper
This paper
This paper
This paper
This paper
This paper
This paper

GDI1, GDP dissociation inhibitor 1. Note that the presence of GDI1 is not relevant to these experiments.
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0.2 mg/ml zymolyase 100T in KPi buffer, pH 7.3 (1 ml/5 OD unit cells). An
aliquot of the cells was collected in a microfuge tube and the pellet was incubated with 2% OsO4 for 1 h followed by incubation with 1% uranyl acetate (aqueous) at 4C for 30 min. The pellets were dehydrated with sequential ethanol washes and incubated with 50% ethanol/50% SPURR
resin (Electron Microscopy Sciences), then changed to 100% SPURR, and
the sample was transferred to beem capsules (Electron Microscopy Sciences) and baked at 70C for at least 24 h. Thin sections were cut onto
3-mm-diam 75/300-type mesh copper specimen grids (Veco), contrasted
with lead citrate and uranyl acetate, and examined in an electron microscope (model 201; Philips) at 80 kV.
For fluorescence microscopy, the GFP-KDEL construct was generated in
plasmid pRS316 (Sikorski and Hieter, 1989) using standard molecular biology techniques. In brief, the construct comprises 363 bp of the KAR2 promoter with 45 amino acids of the Kar2p presequence fused to a linker
(GGPGG) followed by yeast-enhanced GFP (yEGFP; Cormack et al.,
1997), which in turn is followed by second linker (GGPGG) and the sequence HDEL. The ADH1 3 region (572 bp) was added after the stop
codon to provide transcription termination. The GFP amino-terminal fusions of GOS1, SED5, and SFT2 were also constructed in plasmid pRS316.
Each construct contains 238 amino acids of yEGFP fused to the start methionine of the tagged protein preceded by a linker (GGPGG). The fusions are
driven by 452 bp of the YOP1 promoter and contain the endogenous gene
terminator (441 bp, 378 bp, and 553 bp of the noncoding 3 region for
SED5, GOS1, and SFT2, respectively). GFP-YIP1 was constructed by inserting yEGFP after the initiator methionine in pRS315-YIP1, leaving the
endogenous promoter intact. This construct (pRC693) was expressed at
wild-type levels in haploid cells as the only source of YIP1. Cells containing GFP fusion plasmids were examined with a microscope (Eclipse E600;
Nikon) equipped with a 60 objective and 2 optovar. A Spot-RT monochrome CCD camera (Diagnostic Instruments)with version 3.5 software
was used for image capture. All images shown are representative images
from cells during logarithmic phase growth in minimal media supplemented as necessary.
We thank Dieter Gallwitz (Max Planck Institute, Göttingen, Germany) for
providing strains and antibodies used in the early stages of this work. We
also thank A. Damon Ferguson for valuable assistance with EM and Susan
Henry (Cornell University, Ithaca, NY) for providing strains.
This work was supported by grants from the American Heart Association (0030316T) and the National Science Foundation (MCB0079045) to
R.S. Collins, and from the National Institutes of Health (GM52549) to C.
Barlowe.
Submitted: 23 June 2003
Accepted: 26 August 2003

References
Allan, B.A., B.D. Moyer, and W.E. Balch. 2000. Rab1 recruitment of p115 into a
cis-SNARE complex: programming budding of COPII vesicles for fusion.
Science. 289:444–448.
Ausubel, R.M., R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith,
and K. Struhl. 1987. Current Protocols in Molecular Biology. Greene Publishing Associates and Wiley-InterScience, New York. 3.0.1–3.14.3.
Baker, D., L. Hicke, M. Rexach, M. Schleyer, and R. Schekman. 1988. Reconstitution of SEC gene product-dependent intercompartmental protein transport.
Cell. 54:335–344.
Barlowe, C. 1997. Coupled ER to Golgi transport reconstituted with purified cytosolic proteins. J. Cell Biol. 139:1097–1108.
Barlowe, C., L. Orci, T. Yeung, M. Hosobuchi, S. Hamamoto, N. Salama, M.
Rexach, M. Ravazzola, M. Amherdt, and R. Schekman. 1994. COPII: a
membrane coat formed by Sec proteins that drive vesicle budding from the
ER. Cell. 77:895–907.
Barrowman, J., W. Wang, Y. Zhang, and S. Ferro-Novick. 2003. The Yip1p/Yif1p
complex is required for the fusion competence of endoplasmic reticulumderived vesicles. J. Biol. Chem. 278:19878–19884.
Becker, J., T.J. Tan, H.-H. Trepte, and D. Gallwitz. 1991. Mutational analysis of
the putative effector domain of the GTP-binding Ypt1 protein in yeast suggests specific regulation by a novel GAP activity. EMBO J. 10:785–792.
Belden, W.J., and C. Barlowe. 2001a. Deletion of yeast p24 genes activates the unfolded protein response. Mol. Biol. Cell. 12:957–969.
Belden, W.J., and C. Barlowe. 2001b. Role of Erv29p in collecting soluble secretory proteins into ER-derived transport vesicles. Science. 294:1528–1531.

Calero, M., and R.N. Collins. 2002. Saccharomyces cerevisiae Pra1p/Yip3p interacts
with Yip1p and Rab proteins. Biochem. Biophys. Res. Commun. 290:676–
681.
Calero, M., N.J. Winand, and R.N. Collins. 2002. Identification of the novel proteins Yip4p and Yip5p as Rab GTPase interacting factors. FEBS Lett. 515:
89–98.
Calero, M., C.Z. Chen, W. Zhu, N. Winand, K.A. Havas, P.M. Gilbert, C.G.
Burd, and R.N. Collins. 2003. Dual prenylation is required for Rab protein
localization and function. Mol. Biol. Cell. 14:1852–1867.
Cao, X., and C. Barlowe. 2000. Asymmetric requirements for a Rab GTPase and
SNARE proteins in fusion of COPII vesicles with acceptor membranes. J.
Cell Biol. 149:55–65.
Cao, X., N. Ballew, and C. Barlowe. 1998. Initial docking of ER-derived vesicles
requires Uso1p and Ypt1p but is independent of SNARE proteins. EMBO J.
17:2156–2165.
Carroll, K.S., J. Hanna, I. Simon, J. Krise, P. Barbero, and S.R. Pfeffer. 2001. Role
of Rab9 GTPase in facilitating receptor recruitment by TIP47. Science. 292:
1373–1376.
Cormack, B.P., G. Bertram, M. Egerton, N.A. Gow, S. Falkow, and A.J. Brown.
1997. Yeast-enhanced green fluorescent protein (yEGFP) a reporter of gene
expression in Candida albicans. Microbiol. 143:303–311.
Harlow, E., and D. Lane. 1988. Antibodies: A Laboratory Manual. Cold Spring
Harbor Laboratory Press, Cold Spring Harbor, NY. 312–319.
Hosobuchi, M., T. Kreis, and R. Schekman. 1992. SEC21 is a gene required for
ER to Golgi protein transport that encodes a subunit of the yeast coatomer.
Nature. 360:603–605.
Kaiser, C., and R. Schekman. 1990. Distinct sets of SEC genes govern transport
vesicle formation and fusion in the early secretory pathway. Cell. 61:723–
733.
Liu, Y., and C. Barlowe. 2002. Analysis of Sec22p in endoplasmic reticulum/Golgi
transport reveals cellular redundancy in SNARE protein function. Mol. Biol.
Cell. 13:3314–3324.
Matern, H., X. Yang, E. Andrulis, R. Sternglanz, H.-H. Trepte, and D. Gallwitz.
2000. A novel Golgi membrane protein is part of a GTPase-binding protein
complex involved in vesicle targeting. EMBO J. 19:4485–4492.
Matsuoka, K., L. Orci, M. Amherdt, S.Y. Bednarek, S. Hamamoto, R. Schekman,
and T. Yeung. 1998. COPII-coated vesicle formation reconstituted with purified coat proteins and chemically defined liposomes. Cell. 93:263–275.
McNew, J.A., J.G. Coe, M. Sogaard, B.V. Zemelman, C. Wimmer, W. Hong, and
T.H. Sollner. 1998. Gos1p, a Saccharomyces SNARE protein involved in
Golgi transport. FEBS Lett. 435:89–95.
Mellman, I., and G. Warren. 2000. The road taken: past and future foundations of
membrane traffic. Cell. 100:99–112.
Miller, E., B. Antonny, S. Hamamoto, and R. Schekman. 2002. Cargo selection
into COPII vesicles is driven by the Sec24p subunit. EMBO J. 21:6105–
6113.
Novick, P., C. Field, and R. Schekman. 1980. Identification of 23 complementation groups required for post-translational events in the yeast secretory pathway. Cell. 21:205–215.
Otte, S., W.J. Belden, M. Heidtman, J. Liu, O.N. Jensen, and C. Barlowe. 2001.
Erv41p and Erv46p: new components of COPII vesicles involved in transport between the ER and the Golgi complex. J. Cell Biol. 152:503–518.
Pelham, H.R.B. 2001. SNAREs and the specificity of membrane fusion. Trends
Cell Biol. 11:99–101.
Rexach, M.F., and R. Schekman. 1991. Distinct biochemical requirements for the
budding, targeting, and fusion of ER-derived transport vesicles. J. Cell Biol.
114:219–229.
Rexach, M.F., M. Latterich, and R.W. Schekman. 1994. Characteristics of endoplasmic reticulum-derived transport vesicles. J. Cell Biol. 126:1133–1148.
Schroder, S., F. Schimmoler, B. Singer-Kruger, and H. Riezman. 1995. The Golgilocalization of yeast Emp47p depends on its di-lysine motif but is not affected by the ret1-1 mutation in -COP. J. Cell Biol. 131:895–912.
Segev, N. 1991. Mediation of the attachment or fusion step in vesicular transport
by the GTP-binding Ypt1 protein. Science. 252:1553–1556.
Segev, N. 2001. Ypt and Rab GTPases: insight into functions through novel interactions. Curr. Opin. Cell Biol. 13:500–511.
Segev, N., J. Mulholland, and D. Botstein. 1988. The yeast GTP-binding Ypt1
protein and a mammalian counterpart are associated with the secretion machinery. Cell. 52:915–924.
Sherman, F. 1991. Getting started with yeast. Methods Enzymol. 194:3–20.
Sikorski, R.S., and P.A. Hieter. 1989. A system of shuttle vectors and yeast host
strains designed for efficient manipulation of DNA in Saccharomyces cerevi-

Yip1p in COPII vesicle biogenesis | Heidtman et al. 69

The Journal of Cell Biology

siae. Genetics. 122:19–27.
Tang, B.L., Y.S. Ong, B. Huang, S. Wei, E.S. Wong, R. Qi, H. Horstmann, and
W. Hong. 2001. A membrane protein enriched in endoplasmic reticulum
exit sites interacts with COPII. J. Biol. Chem. 276:40008–40017.
Tsui, M.M.K., W.C.S. Tai, and D.K. Banfield. 2001. Selective formation of
Sed5p-containing SNARE complexes is mediated by combinatorial binding
interactions. Mol. Biol. Cell. 12:521–538.
Ward, T.H., R.S. Polishchuk, S. Caplan, K. Hirschberg, and J. LippincottSchwartz. 2001. Maintenance of Golgi structure and function depends on
the integrity of ER export. J. Cell Biol. 155:557–570.
Wilson, D.W., C.A. Wilcox, G.C. Flynn, E. Chen, W. Kuang, W.J. Henzel, M.R.
Block, A. Ullrich, and J.E. Rothman. 1989. A fusion protein is required for
vesicle-mediated transport in both mammalian cells and yeast. Nature. 339:

355–359.
Winston, F., C. Dollard, and L.L. Ricupero-Hovasse. 1995. Construction of a set
of convenient Saccharomyces cerevisiae strains that are isogenic to S288C.
Yeast. 11:53–55.
Wooding, S., and H.R.B. Pelham. 1998. The dynamics of Golgi protein traffic visualized in living yeast cells. Mol. Biol. Cell. 9:2667–2680.
Wright, R., M. Basson, L. D’Ari, and J. Rine. 1988. Increased amounts of HMGCoA reductase induce “karmellae”: a proliferation of stacked membrane
pairs surrounding the yeast nucleus. J. Cell Biol. 107:101–114.
Yang, X., H.T. Matern, and D. Gallwitz. 1998. Specific binding to a novel and essential Golgi membrane protein (Yip1p) functionally links the transport
GTPases Ypt1p and Ypt31p. EMBO J. 17:4954–4963.

